Paviour Pharmaceuticals Pvt Ltd
Poractant Alfa (80mg)
Curosurf 80mg Injection is used for respiratory distress syndrome (immature lungs in preterm baby) to treat or prevent Respiratory Distress Syndrome (RDS) in newborn babies.
Injection
Curosurf 80mg Injection is given under the supervision of a healthcare professional in the hospital setting. Your doctor will decide how much you need to improve your symptoms. Infants are continuously monitored to avoid any medical emergency. Pneumothorax, brain hemorrhage, chronic lung disease, decreased oxygen level in the blood, and infection are some serious side effects of this medicine. Your doctor will be the best person to decide how to overcome the side effects.
Your doctor or nurse will give you this medicine. Kindly do not self-administer.
No common side effects listed.
It is not known whether it is safe to consume alcohol with Curosurf 80mg Injection. Please consult your doctor.
Information regarding the use of Curosurf 80mg Injection during breastfeeding is not available. Please consult your doctor.
Information regarding the use of Curosurf 80mg Injection during pregnancy is not available. Please consult your doctor.
Curosurf 80mg Injection is the surfactant given to premature babies to protect their lungs. The surfactant is a fatty substance that coats the inside or lining of the air sacs in the lungs. This coating prevents the air sacs from collapsing and sticking together when air leaves the lungs. The surfactant is produced by babies only after the 8th month of pregnancy.
Curosurf 80mg Injection is to treat or prevent Respiratory Distress Syndrome (RDS) in newborn babies. It is to be administered under the supervision of a medical expert. Your child will be closely monitored for any signs of infection or distress while receiving Curosurf 80mg Injection. It is to be administered under the supervision of a medical expert. Your child will be closely monitored for any signs of infection or distress while receiving Curosurf 80mg Injection.
Curosurf 80mg Injection is a pulmonary surfactant replacement therapy that helps to reduce the surface tension within the lungs, thereby preventing the air sacs from collapsing and allowing for easier breathing. It is specifically designed for use in newborn infants who have been diagnosed with respiratory distress syndrome (RDS), often due to insufficient or absent surfactant production.